Metabolomics News and Research

Latest Metabolomics News and Research

Researchers discover two new metabolic pathways

Case Western Reserve University researchers, from the School of Medicine's Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abuse, known as 4-hydroxyacids, are metabolized.

5 Dec 2009

NIGMS invests $42.3 million in "Grand Opportunities" grant

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), is investing $42.3 million for grants in scientific areas it identified as "Grand Opportunities (GO)." NIH developed the GO grant program to stimulate biomedical research and the economy using funds provided by the American Recovery and Reinvestment Act (Recovery Act).

24 Nov 2009

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Duke University and Jubilant Organosys Limited, the largest integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company in India, through its subsidiary, Jubilant Biosys Limited, today signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies.

11 Nov 2009

Scientists receive $3 million from NIH to uncover how plants make medicinal compounds

Scientists at Michigan State University are receiving nearly $3 million from the National Institutes of Health to uncover how several popular plants make medicinal compounds.

6 Nov 2009

Metabolon raises additional $6 million in its Series C funding round

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today that it has closed an additional $6 million in its Series C funding round. This brings the total funding raised in the company’s series C round to $12.3 million.

27 Oct 2009

Syngenta Ventures makes equity investment in Metabolon

Syngenta Ventures announced today that it has made an equity investment in Metabolon, a privately-held U.S. biotechnology company focused on the use of metabolomics in research and diagnostics.

27 Oct 2009

Researchers develop a non-invasive test to help assess embryo viability for IVF

Embryos that are most likely to result in a pregnancy are crucial to the success of in vitro fertilization (IVF) but are difficult to identify. Researchers at Yale School of Medicine, led by Emre Seli, M.D., are developing a fast, non-invasive test to help assess embryo viability for IVF.

22 Oct 2009

University of Florida to build a new research facility in Orlando

The University of Florida (UF) has reached a milestone in its efforts to build a research facility in Orlando at the emerging Lake Nona Medical City. A ceremony marking the official signing of the agreements was held immediately preceding the formal dedication of Burnham Institute for Medical Research’s (Burnham) Lake Nona campus.

13 Oct 2009

Burnham Institute officially dedicates its new research facility at Lake Nona

Today, Burnham Institute for Medical Research (Burnham) officially dedicated its new 175,000-square-foot scientific facility and marked the opening of Orlando’s Medical City as a life science center. Burnham at Lake Nona is the research anchor for the new development in southeast Orange County and the east coast campus of the La Jolla, Calif.-based institute.

9 Oct 2009

Metabolomics identifies biomarkers for periodontitis and gingivitis

...

30 Sep 2009

Research program to study personalized medicine

A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.

18 Sep 2009

Mechanism of action of the anti-cancer drug GMX1778 identified

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper “The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors” appears online ahead of print in Molecular and Cellular Biology.

17 Sep 2009

Metabolon awarded patent for metabolomics software

Metabolon, Inc. has announced that it has been awarded a patent for its metabolomics software, Ion Tracker™, which provides a mechanism for creating new chemical library entries.

11 Aug 2009

New approach to prostate cancer detection - Sarcosine may distinguish between slow-growing and aggressive prostate cancers

On Friday 20 March, US researcher Dr. Chris Beecher from the University of Michigan gave a well attended lecture about sarcosine, an N-methyl derivative of the amino acid glycine, at the 24th Annual EAU Congress in Stockholm, Sweden.

25 Mar 2009